BidaskClub upgraded shares of Revance Therapeutics (NASDAQ:RVNC) from a sell rating to a hold rating in a research note published on Thursday morning, BidAskClub reports.

Other equities research analysts also recently issued research reports about the company. Barclays initiated coverage on Revance Therapeutics in a report on Tuesday, June 11th. They issued an overweight rating and a $28.00 price objective on the stock. ValuEngine upgraded Revance Therapeutics from a sell rating to a hold rating in a report on Thursday, August 1st. William Blair reiterated an outperform rating on shares of Revance Therapeutics in a report on Tuesday, August 6th. Finally, Zacks Investment Research upgraded Revance Therapeutics from a sell rating to a hold rating in a report on Friday, August 9th. Five analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The company has an average rating of Buy and an average price target of $33.09.

Shares of RVNC stock traded up $0.01 on Thursday, hitting $12.99. The stock had a trading volume of 12,620 shares, compared to its average volume of 332,399. The company has a debt-to-equity ratio of 0.15, a current ratio of 5.59 and a quick ratio of 5.59. The firm has a market capitalization of $553.49 million, a P/E ratio of -3.29 and a beta of 1.16. Revance Therapeutics has a 1 year low of $9.88 and a 1 year high of $26.89. The company’s 50 day moving average price is $11.54 and its 200-day moving average price is $12.98.

Revance Therapeutics (NASDAQ:RVNC) last posted its quarterly earnings data on Monday, August 5th. The biopharmaceutical company reported ($0.86) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.86). Revance Therapeutics had a negative return on equity of 79.28% and a negative net margin of 3,745.97%. On average, equities analysts forecast that Revance Therapeutics will post -3.73 EPS for the current year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. grew its stake in Revance Therapeutics by 2.4% during the 1st quarter. JPMorgan Chase & Co. now owns 3,897,870 shares of the biopharmaceutical company’s stock worth $61,431,000 after purchasing an additional 92,811 shares in the last quarter. Vanguard Group Inc. grew its stake in Revance Therapeutics by 7.0% during the 2nd quarter. Vanguard Group Inc. now owns 2,249,144 shares of the biopharmaceutical company’s stock worth $29,172,000 after purchasing an additional 146,444 shares in the last quarter. Renaissance Technologies LLC grew its stake in Revance Therapeutics by 47.5% during the 2nd quarter. Renaissance Technologies LLC now owns 1,330,973 shares of the biopharmaceutical company’s stock worth $17,263,000 after purchasing an additional 428,900 shares in the last quarter. Rice Hall James & Associates LLC grew its stake in Revance Therapeutics by 654.1% during the 2nd quarter. Rice Hall James & Associates LLC now owns 882,769 shares of the biopharmaceutical company’s stock worth $11,450,000 after purchasing an additional 765,701 shares in the last quarter. Finally, Bamco Inc. NY grew its stake in Revance Therapeutics by 24.7% during the 2nd quarter. Bamco Inc. NY now owns 635,200 shares of the biopharmaceutical company’s stock worth $8,239,000 after purchasing an additional 126,000 shares in the last quarter. 98.75% of the stock is owned by hedge funds and other institutional investors.

About Revance Therapeutics

Revance Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development, manufacture, and commercialization of novel neuromodulators for various aesthetic and therapeutic indications. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI), which is in phase III clinical trials to treat glabellar (frown) lines and cervical dystonia; and in phase II clinical trials for the treatment of plantar fasciitis, adult upper limb spasticity, and chronic migraine.

See Also: Why are trading ranges significant?

Analyst Recommendations for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.